Organ Index Determination in Mastitis Mouse Models: Principles, Methodology, and Applications

Organ index determination, defined as the ratio of organ wet weight to body weight, is a sensitive and reproducible endpoint for quantifying inflammatory responses and systemic organ changes in mastitis mouse models. This assay delivers objective data on mammary gland inflammation, immune organ modulation, and potential hepatorenal toxicity, supporting preclinical efficacy and safety evaluation of therapeutic candidates. This article outlines the technical principles, sample types, testing items, measurement protocols, and practical applications of organ index testing in experimental mastitis research conducted by accredited third-party laboratories under GLP-aligned conditions.

Technical Overview

Organ index, also known as the organ coefficient or viscerosomatic index, is calculated by dividing the wet weight of a freshly dissected organ by the body weight of the animal, and is conventionally expressed as a percentage (organ weight/body weight × 100) or as milligrams of organ weight per gram of body weight. In murine mastitis research, this metric is a cornerstone quantitative endpoint because inflamed mammary tissue undergoes edematous swelling, vascular congestion, and dense inflammatory cell infiltration that measurably increase gland weight, whereas effective anti-inflammatory interventions normalize the elevated value.

Mastitis is typically established in mice by intramammary inoculation of lipopolysaccharide (LPS) or clinical isolates such as Staphylococcus aureus, Escherichia coli, or Streptococcus agalactiae through the teat canal of lactating dams, or by hormone-based protocols in non-lactating females. After model establishment and dosing, a single necropsy yields organ index data that simultaneously reflect local disease severity in the mammary gland, immunological status through the spleen and thymus, and systemic tolerability through the liver and kidneys.

Because the data are numerical, rapid to acquire, and highly reproducible, organ index measurement is routinely paired with histopathology, myeloperoxidase (MPO) activity assays, cytokine quantification (TNF-alpha, IL-1beta, IL-6), and hematology to construct a comprehensive description of disease progression and therapeutic response.

Testing Samples

Mammary Gland Tissue

The inguinal (fourth pair) mammary glands are the primary target tissue. At the scheduled endpoint, glands are excised with careful removal of adjacent adipose tissue and regional lymph nodes, blotted gently with filter paper to remove surface blood and moisture, and weighed immediately to prevent desiccation artifacts. Bilateral glands may be weighed individually or combined depending on the study protocol.

Immune Organs: Spleen and Thymus

The spleen and thymus are collected to evaluate immunological consequences of mastitis and of test article administration. Splenomegaly frequently accompanies systemic inflammation and infection, whereas thymic involution may indicate stress or immunosuppression. Restitution of these indices toward control values suggests immunomodulatory or protective activity of the test substance.

Liver and Kidneys

The liver and kidneys serve as sentinel organs for systemic exposure and toxicity. Significant enlargement or reduction of these organs relative to controls provides an early quantitative warning of adverse effects that should subsequently be confirmed by serum biochemistry and histopathological examination.

Additional Organs

Heart, lungs, adrenal glands, uterus, and ovaries can be included when the study design requires broader systemic surveillance, for example in repeat-dose toxicity screening or when reproductive endpoints are of interest.

Testing Items

• Mammary gland index (primary efficacy endpoint)
• Spleen index
• Thymus index
• Liver index
• Kidney index (left, right, or combined)
• Lung index
• Heart index (optional)
• Terminal body weight and body weight change profile

Each index is reported per animal and summarized as a group mean with standard deviation or standard error, accompanied by intergroup statistical comparison.

Testing Methods

Experimental Design and Grouping

A standard layout includes a blank (sham) control group, a model control group, a positive drug reference group, and the test article at low, medium, and high dose levels. Female BALB/c, C57BL/6, ICR, or Kunming mice of defined age and weight are randomized to groups, commonly with six to ten animals per group, and investigators are blinded to treatment allocation during dissection and weighing.

Model Induction

Lactating dams or hormone-primed females are lightly anesthetized, and an LPS solution or a calibrated bacterial suspension is infused through the teat canal in a small fixed volume. Model success is confirmed by clinical observation (gland swelling, erythema, lethargy), subsequent histological examination, and elevated inflammatory biomarkers.

Euthanasia, Necropsy, and Dissection

Terminal body weight is recorded immediately before euthanasia using an approved method consistent with institutional animal care protocols. A systematic necropsy is then performed: organs are harvested in a fixed order, trimmed free of fat and connective tissue using consistent anatomical boundaries, rinsed in cold isotonic saline when necessary, and blotted to a standardized dryness.

Weighing and Calculation

All organs are weighed on a calibrated analytical balance with a readability of 0.1 mg. The organ index is calculated as: organ index (%) = organ wet weight (g) / terminal body weight (g) × 100. Weighing is completed within minutes of dissection to avoid moisture loss, and balance calibration records are retained as part of the study archive.

Statistical Analysis

Normality and variance homogeneity are verified, followed by one-way analysis of variance (ANOVA) with Dunnett or Tukey post hoc tests, or by nonparametric alternatives such as the Kruskal-Wallis test when assumptions are not met. Differences are conventionally considered significant at probability levels below 0.05.

Quality Assurance and Standards Framework

Studies are executed in accredited third-party laboratories observing national laboratory animal standards (including GB 14922, GB 14923, GB 14924, and GB 14925 covering animal quality, nutrition, and housing), with protocols approved by the institutional ethics committee. Endpoint logic is aligned with internationally recognized toxicity frameworks such as OECD Test Guideline 407, in which organ weights are core parameters, and data generation follows OECD Principles of Good Laboratory Practice and ISO/IEC 17025 quality management requirements.

Applications

• Efficacy evaluation of anti-inflammatory drugs, antibiotics, and biological agents against LPS-induced or bacterial mastitis
• Screening of natural products, botanical extracts, peptides, and functional ingredients for mastitis prevention and treatment
• Immunomodulatory assessment based on spleen and thymus index changes
• Early preclinical safety screening for hepatorenal burden of candidate therapeutics
• Mechanistic research on inflammatory signaling, oxidative stress, and barrier dysfunction in mammary tissue
• Evaluation of feed additives, probiotics, and nutraceuticals relevant to dairy herd health and translational pharmacology

FAQ

Why is organ weight normalized to body weight?

Normalizing organ weight to terminal body weight removes the confounding influence of animal size, allowing meaningful comparison across individuals, treatment groups, and studies. Absolute organ weights alone can misrepresent organ-specific changes when body weight differs substantially between groups.

How is an elevated mammary gland index interpreted?

An elevated index reflects edema, hyperemia, and inflammatory infiltration in the gland and correlates with disease severity. A statistically significant reduction of the index toward blank control values indicates that the test article attenuates mammary inflammation, a conclusion that should be corroborated by histopathology and MPO or cytokine data.

What sample size is recommended?

Most published mastitis studies use six to ten mice per group to detect biologically meaningful differences in organ indices. A formal power analysis based on pilot variability is recommended to justify the final sample size while respecting the principles of replacement, reduction, and refinement (3Rs).

At which time points should organ index be measured?

For LPS-induced models, endpoints typically fall between 12 and 48 hours after inoculation, corresponding to peak inflammatory responses. Bacterial models may extend to 48 to 72 hours or later, and repeat-dose safety studies follow the dosing schedule defined in the protocol, with terminal necropsy performed after the final administration.

Can organ index testing be combined with other endpoints?

Yes. Organs weighed at necropsy can subsequently be fixed for histopathological scoring, homogenized for MPO activity and cytokine quantification, or processed for molecular assays, enabling a multi-dimensional evaluation of efficacy and safety from the same cohort of animals.